Antibodies News and Research

RSS

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers in Austria have conducted a study showing that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a significantly more pronounced antibody response to one dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine than previously uninfected individuals.

3 Aug 2021

Researchers develop a new way to detect placenta accreta spectrum disorder during pregnancy

Researchers from UCLA and Cedars-Sinai have developed a new way to detect a potentially life-threatening condition that can occur during pregnancy.

3 Aug 2021

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.

3 Aug 2021

New moms latched on to remote breastfeeding help. Will demand wane as pandemic fades?

Madison Cano knew she wanted to breastfeed her son, Theo. But breastfeeding was painful for her. The skin on her breasts was chafed and blistered last July when she returned home from the hospital. And Theo sometimes screamed during feedings.

3 Aug 2021

CHOP researchers identify two proteins that could be used for a potential NTHi vaccine

Scientists at Children's Hospital of Philadelphia have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae (NTHi).

2 Aug 2021

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers in Singapore have conducted a study showing that the messenger RNA- (mRNA) based coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna are highly effective at protecting against symptomatic and severe disease following infection with the rapidly spreading B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

A new study reports the use of a modified deoxyribonucleic acid (DNA) oligonucleotide that has a 3’ polyadenine (polyA) tail to bind to the 5’-polyU tract in the mouse coronavirus (MHV-A59). Treatment of mouse cells infected with MHV-A59 with this molecule led to a marked reduction in cell deaths.

2 Aug 2021

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

An intriguing new study presents a novel approach to biosensor-based evaluation of promising drugs that could inhibit the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via its 3C-like protease (3CLpro), a viral protease.

2 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

A new study published in The New England Journal of Medicine found that in a very small number of cases, people with breakthrough infections might suffer long-lasting COVID-19 symptoms.

2 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Researchers conducting a serosurveillance study of a North American deer species have provided evidence of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the animals across four U.S. states.

1 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Highly Efficient Exosome Isolation & Purification Tools

AMSBIO is a knowledgeable supplier of products dedicated to exosome research that includes high quality reagents and kits that are quick, affordable and easy to use.

From AMS Biotechnology 1 Aug 2021

Amid covid booster debate, West Virginia to check immunity of vaccinated nursing home residents

West Virginia raced ahead of the country last winter to get people in nursing homes vaccinated against covid-19, but with cases and hospitalizations on the rise again, state officials want to know whether immunity levels are falling for residents who had their shots.

30 Jul 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Antibodies News and Research

“Sybodies” protect against SARS-CoV-2 in hamster model

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers develop a new way to detect placenta accreta spectrum disorder during pregnancy

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

New moms latched on to remote breastfeeding help. Will demand wane as pandemic fades?

CHOP researchers identify two proteins that could be used for a potential NTHi vaccine

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Highly Efficient Exosome Isolation & Purification Tools

Amid covid booster debate, West Virginia to check immunity of vaccinated nursing home residents

BNT162b2 vaccine shows high efficacy at six months

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News